CClinicalTrials.gg
Not yet recruitingNCT07507097Updated Apr 2, 2026

Study on the Optimal Head Position for Patients With Severe Acute Ischemic Stroke

An interventional study of head position in Stroke Acute, sponsored by West China Hospital. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-02.

Sponsored by West China Hospital · Not applicable, Interventional, and Supportive care

Phase
Not applicable
Study type
Interventional
Enrollment
1,508
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Stroke is the second leading cause of death and the third leading cause of disability worldwide, with an increasing incidence. Reperfusion therapy after cerebral ischemia is one of the most practical and effective treatments for ischemic stroke globally. However, the nursing care and management of hemodynamics during the acute phase after reperfusion therapy for ischemic stroke have always been key and challenging aspects of clinical work. Stable hemodynamic status can prevent hypoperfusion or hyperperfusion of brain tissue, reduce damage to the ischemic core and penumbra areas, and consequently decrease cerebral edema, elevated intracranial pressure, and the associated neurological damage and worsening clinical outcomes.

Head positioning, as a simple, economical, and effective adjunctive treatment for managing patients undergoing reperfusion therapy, has gradually received attention. During the acute phase of stroke, brain tissue is in a state of ischemia and hypoxia. Lying flat may increase blood and oxygen supply to the brain tissue, providing a certain degree of protection, but it may also have some impact on swallowing and lung function. Raising the head of the bed can help venous blood return from the head and may reduce cerebral edema to some extent, but it can also affect perfusion of ischemic brain tissue to a certain degree. In the acute phase after successful reperfusion, it remains a clinical challenge to maintain stable cerebral blood supply (hemodynamic stability) through nursing care. Head positioning (lying flat or elevating the head of the bed) is a simple, economical nursing measure that may affect cerebral blood flow. However, for severely affected stroke patients like you, there is no clear international consensus on whether maintaining a flat position (0°) or elevating the head of the bed 30° within the first 24 hours after treatment is more beneficial for long-term recovery. Previous studies have shown inconsistent results, so more rigorous research is needed to answer this question.

The primary purpose of this study is to determine that a 30° position during the acute phase of severe ischemic stroke is safe. The secondary purpose is to evaluate whether a 30° position in the acute phase improves 90-day outcomes compared to a 0° position (assessed using the modified Rankin Scale).

This study is a randomized controlled trial. This means you will be randomly assigned (like a coin toss) to one of the following two groups: Experimental group: within 24 hours of admission, maintain the head and bed elevated at 30°. Control group: within 24 hours of admission, remain completely flat (0°). Interventions and methods: Both head positions are commonly used basic nursing measures in neurological intensive care. Lying flat may help increase blood supply to the brain, while elevating the head of the bed may help reduce cerebral edema and the risk of aspiration. This study aims to scientifically compare which angle is better for your long-term recovery. Procedures: Research nurses will use a special angle ruler to ensure your head position is accurate. During the 24-hour intervention, we need you to maintain the assigned position as much as possible. Considering your comfort and necessary medical care (such as back patting and skin inspection), brief interruptions are allowed (no more than three times for the flat position group, with each interruption less than 30 minutes). Legal Compliance: Head positioning management is a routine nursing procedure. This study only conducted standardization and comparative research on it, and did not involve the use of any experimental drugs or high-risk devices. It has passed ethical review.

02

Conditions studied

  • Stroke Acute

Browse trials for

03

In context

Stroke

7,286 studies on the registry are indexed under Stroke; 2,007 are open to participants now.

This study's planned enrollment of 1,508 is above the median of 50 across 5,369 interventional studies indexed under Stroke.

Browse Stroke studies →

Lead sponsor

West China Hospital is the lead sponsor of 483 studies on the registry; 240 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Age ≥ 18 years
  2. Meeting the diagnostic criteria for acute ischemic stroke according to the "Chinese Guidelines for the Diagnosis and Treatment of Acute Ischemic Stroke 2023": ①Acute onset, ②Focal neurological deficits, with a few having global neurological deficits, ③Imaging shows a corresponding lesion or symptoms/signs persist for more than 24 hours, ④Exclusion of non-vascular causes, ⑤Brain CT/MRI excludes cerebral hemorrhage
  3. Meeting the criteria for severe ischemic stroke patients: severe neurological deficits at admission [for example, National Institutes of Health Stroke Scale (NIHSS) score≥15]
  4. First-time diagnosed ischemic stroke patients who undergo thrombolysis and/or thrombectomy reperfusion treatment
  5. Time from onset to randomization within 24 hours
  6. Informed consent obtained and signed by the patient or their family

Exclusion criteria

Exclusion Criteria

  1. Known pregnancy or breastfeeding, or positive pregnancy test before randomization
  2. Expected survival time less than 3 months (such as with malignant tumors, severe cardiopulmonary diseases, etc)
  3. Already participating in other interventional clinical studies that may affect outcome assessment
  4. Other situations deemed by the investigator as unsuitable for participation in this study or that may pose significant risks to the patient (such as inability to understand and/or comply with study procedures and/or follow-up due to mental illness, cognitive or emotional disorders)
  5. Presence of brain midline shift or herniation, ventricular mass effect
  6. Patients with limited head elevation (or patients unable to cooperate with postural intervention due to their condition/recovery needs, etc.)
  7. Presence of respiratory infection symptoms such as fever, cough, or sputum production at the time of admission
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
1,508 participants (estimated)

Study arms

  • No intervention
    0-degree head position

    Keep the head flat at 0° (completely lying down) for 24 hours. During this period, including eating and using the toilet, you must remain lying flat, but intermittent interruptions due to necessary nursing operations (such as back patting or skin checks) are allowed, not exceeding a total of 3 times, with each interruption ≤30 minutes.

  • Experimental
    30-degree head position

    Raise the head of the bed by 30° and maintain for 24 hours. Use a standardized angle ruler and position cushion to ensure accuracy of the angle, bed head angle (including pillow)

    Behavioral: head position

Interventions

  • Behavioralhead position

    Raise the head of the bed by 30° and maintain for 24 hours. Use a standardized angle ruler and position cushion to ensure accuracy of the angle, bed head angle (including pillow)

06

What researchers measure

Primary outcomes

  1. Score of Modified Rankin Scale

    Modified Barthel Index (MBI): is a measure of activities of daily living (ADL), which shows the degree of independence of a patient from any assistance. It is an important method used to evaluate the capacity of participants to conduct 10 different ADLs, considered basic ADLs, thus providing a quantitative estimation of their independence level. The mRS is an ordinal scale that ranges from 0 (no symptoms) to 6 (death).

    Time frame: day 90

  2. Patient mortality

    Patient mortality within 90 days, used for safety assessment

    Time frame: day 90

Secondary outcomes

  1. Score of National Institutes of Health Stroke Scale reduced by ≥4 points

    Neurological function improvement

    Time frame: 5-7 days

Other outcomes

  1. The Chinese version of the European Quality of Life Measurement Scale

    The Chinese version of the European Quality of Life Measurement Scale (EQ-5D) , which consisted of the EQ-5D descriptive system, the European Five Dimensions Questionnaire Visual Analogue Scale (EQ-VAS), and the utility index. The EQ-5D descriptive system measured participants' health status in three levels of severity (no problems, moderate problems, and extreme problems) with five dimensions: mobility (MO), self-care (SC), usual activities (UA), pain/discomfort (PD), and anxiety/ depression (AD) . The EQ-VAS score was recorded on a scale with anchor points 0 (worst health state) and 100 (best health state), which reflected patients' knowledge of health. A higher EQ-5D utility index indicated higher levels of QoL.

    Time frame: day 90

  2. Incidence of pneumonia

    Occurrence of pneumonia

    Time frame: Day 90

  3. Serious adverse event

    Safety evaluation, including aspiration, suffocation, pressure injuries, deep vein thrombosis, etc.

    Time frame: DAY 90

07

Study locations

1 site
  • West China Hospital, Sichuan University
    Chengdu, Sichuan 610041, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07507097
Lead sponsor
West China Hospital
Responsible party
Ling Feng (Professor, West China Hospital) — Principal investigator
First posted
Apr 2, 2026
Start date
May 1, 2026 (estimated)
Primary completion
Dec 31, 2028 (estimated)
Completion
Apr 30, 2029 (estimated)
Last update
Apr 2, 2026

Study contacts

ling feng, Master's degree
Contact
fengling216@163.com
08618980602079

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion